Priscilla K. Brastianos, MD

Phase 2 trial shows abemaciclib prolongs disease control in recurrent high‑grade meningioma with NF2/CDK alterations, with 58% PFS at 6 months.

An interim analysis of the phase II study of palbociclib for the treatment of patients with brain metastases harboring CDK alterations was presented at the 2019 Society for NeuroOncology Annual Meeting by Priscilla K. Brastianos, MD, director of the central nervous system brain metastasis program, Massachusetts General Hospital.<br /> &nbsp;